Solving Formulation Challenges Across Modalities: Patient-Centric Nanoparticle Approaches for Small and Large Molecules

Traditional drug formulation often hits a wall when dealing with poor solubility or the limitations of intravenous delivery. Advanced particle engineering offers a powerful alternative by manipulating materials at the nanoscale. For small molecules, controlled expansion techniques can create pure, excipient-free crystalline nanoparticles down to 10 nm directly from solution. This drastic reduction in size enables solid oral dosage forms to achieve over a threefold increase in drug loading compared to conventional amorphous solid dispersions, significantly reducing pill burden while maintaining therapeutic performance.

For biologics, this cross-modality platform facilitates a seamless transition from cumbersome intravenous infusions to patient-friendly subcutaneous injections. By engineering biological nanoparticles as small as 50 nm, formulation scientists can achieve ultra-high concentrations exceeding 400 mg/mL without relying on hyaluronidase. Access the full presentation to explore real-world case studies detailing these breakthroughs in oral and pulmonary delivery.

Speaker: Dr. Christopher Worrall, VP, US Business Development, Nanoform

Dr. Christopher P. Worrall joined Nanoform in May 2021 as VP of U.S. Business Development. With over 18 years of experience in particle engineering and pharmaceutical solid form science, he has contributed to 11 commercial products and holds numerous patents. Previously, he designed and scaled up GMP organic syntheses at SAFC and Merck KGaA. He holds a PhD in synthetic organic chemistry from the University of Manchester and is widely published.